JP2019512507A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512507A5
JP2019512507A5 JP2018549168A JP2018549168A JP2019512507A5 JP 2019512507 A5 JP2019512507 A5 JP 2019512507A5 JP 2018549168 A JP2018549168 A JP 2018549168A JP 2018549168 A JP2018549168 A JP 2018549168A JP 2019512507 A5 JP2019512507 A5 JP 2019512507A5
Authority
JP
Japan
Prior art keywords
composition
agonist
subject
gemfibrozil
pparα
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018549168A
Other languages
English (en)
Japanese (ja)
Other versions
JP7012658B2 (ja
JP2019512507A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/021799 external-priority patent/WO2017160629A1/en
Publication of JP2019512507A publication Critical patent/JP2019512507A/ja
Publication of JP2019512507A5 publication Critical patent/JP2019512507A5/ja
Application granted granted Critical
Publication of JP7012658B2 publication Critical patent/JP7012658B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018549168A 2016-03-15 2017-03-10 アミロイドβタンパク質の排出を刺激する組成物及び方法 Active JP7012658B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662308374P 2016-03-15 2016-03-15
US62/308,374 2016-03-15
PCT/US2017/021799 WO2017160629A1 (en) 2016-03-15 2017-03-10 COMPOSITION AND METHODS FOR STIMULATING CLEARANCE OF AMYLOID-β PROTEIN

Publications (3)

Publication Number Publication Date
JP2019512507A JP2019512507A (ja) 2019-05-16
JP2019512507A5 true JP2019512507A5 (https=) 2020-04-23
JP7012658B2 JP7012658B2 (ja) 2022-02-14

Family

ID=59852353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018549168A Active JP7012658B2 (ja) 2016-03-15 2017-03-10 アミロイドβタンパク質の排出を刺激する組成物及び方法

Country Status (5)

Country Link
US (2) US11135180B2 (https=)
EP (1) EP3429671B1 (https=)
JP (1) JP7012658B2 (https=)
CA (1) CA3017760A1 (https=)
WO (1) WO2017160629A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111084768A (zh) * 2018-10-24 2020-05-01 中国科学院昆明动物研究所 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途
AU2020315331A1 (en) 2019-07-16 2022-02-03 Rush University Medical Center Use of a benzoate containing composition to treat neurodegenerative disorders
EP4281118A4 (en) * 2021-01-20 2025-01-01 Rush University Medical Center Improved treatment for globoid cell leukodsytrophy or krabbe disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532868A (ja) * 2001-05-25 2004-10-28 シェーリング　コーポレイション アルツハイマー病の処置におけるアゼチジノン置換誘導体の使用
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2014089449A1 (en) * 2012-12-07 2014-06-12 Rush University Nedical Center Composition and method for treating neuronal ceroid lipofuscinosis
WO2015173133A1 (en) * 2014-05-12 2015-11-19 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
WO2016201086A1 (en) * 2015-06-12 2016-12-15 Rush University Medical Center Compositions and methods for stimulating adam10-mediated nonamyloidogenic proteolysis of amyloid precursor protein

Similar Documents

Publication Publication Date Title
Castro et al. Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) rat model of Parkinson's disease
Imbimbo et al. Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?
Imbimbo An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease
Jin et al. Minocycline improves postoperative cognitive impairment in aged mice by inhibiting astrocytic activation
JP2023503309A5 (https=)
Fidalgo et al. Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson’s disease
JP2020534270A5 (https=)
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
EA202191079A1 (ru) Способы лечения синдрома ретта с применением фенфлурамина
JP2018509388A5 (https=)
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
AU2015358512B2 (en) Compositions comprising 15-HEPE and methods of treating or preventing fibrosis using same
JP2019512507A5 (https=)
JP2013520448A5 (https=)
Li et al. Ellagic acid (EA) ameliorates Alzheimer's disease by reducing Aβ levels, oxidative stress and attenuating inflammation
Ni et al. Microglial stimulation triggered by intranasal lipopolysaccharide administration produces antidepressant-like effect through ERK1/2-mediated BDNF synthesis in the hippocampus
RU2008134143A (ru) Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения
JP2016505050A5 (https=)
JP2019507786A5 (https=)
CO6400019A1 (es) Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion
JP2016528171A5 (https=)
AR066666A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
WO2022090734A1 (en) Neurodegenerative treatment
CN100355421C (zh) 二十二碳六烯酸作为活性物质制备用于治疗脂肪代谢障碍的药物的用途
RU2353358C2 (ru) Производные прегабалина для лечения приливов